Can a diet and coaching program reverse type 2 diabetes in memphis?

NCT ID NCT07316569

Completed Disease control Sponsor: University of Tennessee Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a 6-month program combining group classes, personal coaching, and a low-carb diet to help people with early type 2 diabetes lose weight and possibly reverse their condition. It involved 35 overweight adults in low-income Memphis neighborhoods. The goal was to see if this approach could lead to diabetes remission, defined as normal blood sugar without medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Intensive multicomponent healthy eating and weight loss intervention (behavioral)
What this could lead to: If successful, this program could offer a practical, low-cost way to help people with early type 2 diabetes achieve remission without medication.
What could go wrong: This is a small pilot study with only 35 participants, so results may not apply to everyone. The program requires significant lifestyle changes, and long-term success is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder Overweight type 2 diabetes mellitus Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETE TYPE 2 DIABETES OVERWEIGHT , OBESITY

Contacts and locations

Locations

UTHSC Health Hub-ShelbyCares

Memphis, Tennessee, 38109, United States
UTHSC Health Hub-Uptown

Memphis, Tennessee, 38105, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.